Vedolizumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Anypodetos (talk | contribs) at 20:06, 13 June 2009 (No ATC code). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Vedolizumab
Monoclonal antibody
Type?
SourceHumanized
TargetLPAM-1
Clinical data
ATC code
  • none
Identifiers
CAS Number
Chemical and physical data
FormulaC6528H10072N1732O2042S42
Molar mass146.8 kDa g·mol−1

Vedolizumab is a monoclonal antibody used in the treatment of ulcerative colitis and Crohn's disease.[1]

This drug was made by Millennium Pharmaceuticals, Inc.

Vedolizumab is undergoing Phase III trials.[2]

References

  1. ^ STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL - VEDOLIZUMAB, American Medical Association.
  2. ^ Clinical trial number NCT00790933 at ClinicalTrials.gov
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Template:Humanizedmonoclonals

Retrieved from "https://en.wikipedia.org/w/index.php?title=Vedolizumab&oldid=296222692"